Clinical Trial Results: Idiopathic Thrombocytopenic Purpura

Protocol Number: ML20948

Product Name: rituximab [MabThera/Rituxan] [rituximab]

Date of Report: 01.07.2012

Phase: II

A multi-centre, single-arm, open-label study to evaluate the efficacy and safety of 1000 mg fixed dose rituximab on days one and fifteen among patients with chronic or relapsing idiopathic thrombocytopenic purpura.
Protocol Number: ML18542

Product Name: rituximab [rituximab]

Date of Report: 01.09.2008

Phase: III

A randomized, open-label study of first-line treatment with dexamethasone or dexamethasone plus MabThera on sustained treatment response in adult patients with idiopathic thrombocytopenic purpura

This database is populated with information on the results of Roche-sponsored clinical trials.

Roche trials database